HC Wainwright initiates coverage on Damora Therapeutics with Buy rating
HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Damora Therapeutics with a Buy rating and a price target of $45. The company is listed on NASDAQ under the ticker DMRA.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Mitchell S. Kapoor has initiated coverage on Damora Therapeutics with a Buy rating and a price target of $45. The rating highlights the firm's positive outlook on the company's performance and future prospects.
Damora Therapeutics is listed on NASDAQ under the ticker symbol DMRA. The initiation of coverage provides a new benchmark for investors evaluating the stock's potential.
Key Details
| Aspect | Details |
|---|---|
| Rating | Buy |
| Price Target | $45 |
| Exchange | NASDAQ |
| Ticker Symbol | DMRA |
| Analyst | Mitchell S. Kapoor |
What upcoming clinical milestones could drive Damora Therapeutics toward the $45 price target?
How might the broader biotech sector trends influence DMRA's performance in the coming months?
What competitive advantages does Damora Therapeutics have that justify the Buy rating?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
